340 related articles for article (PubMed ID: 28296511)
1. Targeted delivery of doxorubicin into tumor cells by nanostructured lipid carriers conjugated to anti-EGFRvIII monoclonal antibody.
Abdolahpour S; Toliyat T; Omidfar K; Modjtahedi H; Wong AJ; Rasaee MJ; Kashanian S; Paknejad M
Artif Cells Nanomed Biotechnol; 2018 Feb; 46(1):89-94. PubMed ID: 28296511
[TBL] [Abstract][Full Text] [Related]
2. Which one performs better for targeted lung cancer combination therapy: pre- or post-bombesin-decorated nanostructured lipid carriers?
Du J; Li L
Drug Deliv; 2016 Jun; 23(5):1799-809. PubMed ID: 26455787
[TBL] [Abstract][Full Text] [Related]
3. Lung cancer combination therapy: co-delivery of paclitaxel and doxorubicin by nanostructured lipid carriers for synergistic effect.
Wang Y; Zhang H; Hao J; Li B; Li M; Xiuwen W
Drug Deliv; 2016 May; 23(4):1398-403. PubMed ID: 26079530
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin-loaded nanocarriers: A comparative study of liposome and nanostructured lipid carrier as alternatives for cancer therapy.
Fernandes RS; Silva JO; Monteiro LOF; Leite EA; Cassali GD; Rubello D; Cardoso VN; Ferreira LAM; Oliveira MC; de Barros ALB
Biomed Pharmacother; 2016 Dec; 84():252-257. PubMed ID: 27664949
[TBL] [Abstract][Full Text] [Related]
5. Transferrin-modified nanostructured lipid carriers as multifunctional nanomedicine for codelivery of DNA and doxorubicin.
Han Y; Zhang Y; Li D; Chen Y; Sun J; Kong F
Int J Nanomedicine; 2014; 9():4107-16. PubMed ID: 25187713
[TBL] [Abstract][Full Text] [Related]
6. Improved pharmacokinetics and enhanced tumor growth inhibition using a nanostructured lipid carrier loaded with doxorubicin and modified with a layer-by-layer polyelectrolyte coating.
Mussi SV; Parekh G; Pattekari P; Levchenko T; Lvov Y; Ferreira LAM; Torchilin VP
Int J Pharm; 2015 Nov; 495(1):186-193. PubMed ID: 26325314
[TBL] [Abstract][Full Text] [Related]
7. Nanocarrier-Based Combination Chemotherapy for Resistant Tumor: Development, Characterization, and Ex Vivo Cytotoxicity Assessment.
Raikwar S; Vyas S; Sharma R; Mody N; Dubey S; Vyas SP
AAPS PharmSciTech; 2018 Nov; 19(8):3839-3849. PubMed ID: 30280350
[TBL] [Abstract][Full Text] [Related]
8. Co-delivery of doxorubicin, docosahexaenoic acid, and α-tocopherol succinate by nanostructured lipid carriers has a synergistic effect to enhance antitumor activity and reduce toxicity.
Lages EB; Fernandes RS; Silva JO; de Souza ÂM; Cassali GD; de Barros ALB; Miranda Ferreira LA
Biomed Pharmacother; 2020 Dec; 132():110876. PubMed ID: 33113428
[TBL] [Abstract][Full Text] [Related]
9. Sclareol is a potent enhancer of doxorubicin: Evaluation of the free combination and co-loaded nanostructured lipid carriers against breast cancer.
Borges GSM; Silva JO; Fernandes RS; de Souza ÂM; Cassali GD; Yoshida MI; Leite EA; de Barros ALB; Ferreira LAM
Life Sci; 2019 Sep; 232():116678. PubMed ID: 31344429
[TBL] [Abstract][Full Text] [Related]
10. Polyarginine and PEG-AEYLR comodified nanostructured lipid carrier: 10mol% uncleavable PEG-AEYLR showed no shielding effect to polyarginine in vitro while maintaining good tumor targeting in vivo.
Sun M; Zhu Z; Wang H; Jin S; Yang X; Han C; Pan W
Artif Cells Nanomed Biotechnol; 2018 Mar; 46(2):284-292. PubMed ID: 28355889
[TBL] [Abstract][Full Text] [Related]
11. Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumour therapy.
Modjtahedi H; Moscatello DK; Box G; Green M; Shotton C; Lamb DJ; Reynolds LJ; Wong AJ; Dean C; Thomas H; Eccles S
Int J Cancer; 2003 Jun; 105(2):273-80. PubMed ID: 12673691
[TBL] [Abstract][Full Text] [Related]
12. pH-sensitive doxorubicin-tocopherol succinate prodrug encapsulated in docosahexaenoic acid-based nanostructured lipid carriers: An effective strategy to improve pharmacokinetics and reduce toxic effects.
Lages EB; Fernandes RS; Andrade MMS; Paiyabhroma N; de Oliveira RB; Fernandes C; Cassali GD; Sicard P; Richard S; Branco de Barros AL; Ferreira LAM
Biomed Pharmacother; 2021 Dec; 144():112373. PubMed ID: 34794238
[TBL] [Abstract][Full Text] [Related]
13. Dimeric c(RGD) peptide conjugated nanostructured lipid carriers for efficient delivery of Gambogic acid to breast cancer.
Kebebe D; Wu Y; Zhang B; Yang J; Liu Y; Li X; Ma Z; Lu P; Liu Z; Li J
Int J Nanomedicine; 2019; 14():6179-6195. PubMed ID: 31447559
[No Abstract] [Full Text] [Related]
14. Functionalized magnetic dextran-spermine nanocarriers for targeted delivery of doxorubicin to breast cancer cells.
Tarvirdipour S; Vasheghani-Farahani E; Soleimani M; Bardania H
Int J Pharm; 2016 Mar; 501(1-2):331-41. PubMed ID: 26875475
[TBL] [Abstract][Full Text] [Related]
15. Redox sensitive PEG controlled octaarginine and targeting peptide co-modified nanostructured lipid carriers for enhanced tumour penetrating and targeting in vitro and in vivo.
Wang H; Sun M; Li D; Yang X; Han C; Pan W
Artif Cells Nanomed Biotechnol; 2018 Mar; 46(2):313-322. PubMed ID: 28362124
[TBL] [Abstract][Full Text] [Related]
16. Small peptide-modified nanostructured lipid carriers distribution and targeting to EGFR-overexpressing tumor in vivo.
Han C; Li Y; Sun M; Liu C; Ma X; Yang X; Yuan Y; Pan W
Artif Cells Nanomed Biotechnol; 2014 Jun; 42(3):161-6. PubMed ID: 23731383
[TBL] [Abstract][Full Text] [Related]
17. Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel.
Liu D; Liu Z; Wang L; Zhang C; Zhang N
Colloids Surf B Biointerfaces; 2011 Jul; 85(2):262-9. PubMed ID: 21435845
[TBL] [Abstract][Full Text] [Related]
18. pH-sensitive PEGylation of RIPL peptide-conjugated nanostructured lipid carriers: design and in vitro evaluation.
Kim CH; Sa CK; Goh MS; Lee ES; Kang TH; Yoon HY; Battogtokh G; Ko YT; Choi YW
Int J Nanomedicine; 2018; 13():6661-6675. PubMed ID: 30425481
[TBL] [Abstract][Full Text] [Related]
19. Design of smart chemotherapy of doxorubicin hydrochloride using nanostructured lipid carriers and solid lipid nanoparticles for improved anticancer efficacy.
Yeo S; Wu H; Yoon I; Lee WK; Hwang SJ
Int J Pharm; 2024 May; 657():124048. PubMed ID: 38537925
[TBL] [Abstract][Full Text] [Related]
20. Combined using of paclitaxel and salinomycin active targeting nanostructured lipid carriers against non-small cell lung cancer and cancer stem cells.
Zhou J; Sun M; Jin S; Fan L; Zhu W; Sui X; Cao L; Yang C; Han C
Drug Deliv; 2019 Dec; 26(1):281-289. PubMed ID: 30880491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
